AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

Inclusion Criteria:

• Male or non-pregnant and non-lactating females aged 21-55 years

• • Report occasional use of cannabis (cannabis use between ≥ biweekly and ≤ 3 daysper week) over the month prior to screening

• Not currently seeking treatment for their cannabis use

• Have a Body Mass Index from 18.5 - 34kg/m2.

• Able to perform all study procedures

• Must be using a contraceptive (hormonal or barrier methods)

• Females must not be lactating

Exclusion Criteria:

• Meeting DSM-V criteria for moderate-severe Cannabis Use disorder (CUD) or anysubstance use disorder other than nicotine, caffeine, or mild CUD

• Any other Axis I disorder

• • Current use of any medications within 14 days or 5 half-lives of administration (whichever is longer) except for hormonal contraceptives in females. If a medicationis taken once a participant is enrolled, sessions will be suspended for 14 days or 5half-lives after administration (whichever is longer)

• If medical history, physical and psychiatric examination, or laboratory testsperformed during the screening process are not within the normal range and / orreveal any significant illness (e.g., hypertension) as judged by the study physicianand to put the participant at greater risk of experiencing adverse events due tocompletion of study procedures.

• Current pain

• Pregnancy is exclusionary due to the possible effects of the study medication onfetal development.

• History of an allergic reaction or adverse reaction to cannabis is exclusionary.

• History of respiratory illness or current respiratory illness

• Currently enrolled in another research protocol

• Not using a contraceptive method (hormonal or barrier methods)

• Insensitivity to the cold water stimulus of the Cold Pressor Test

• Any disorders that might make cannabis administration hazardous are exclusionary, asdetermined by the evaluating physician